ArticleOncology letters2026
Limbic encephalitis associated with anti-Hu antibody induced by atezolizumab treatment for small cell lung cancer: A case report.
Article in Oncology letters, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
With the emergence and frequent use of immune checkpoint inhibitors (ICIs), reports of immunotherapy-induced limbic encephalitis have begun to appear. The present study describes the case of a patient with small cell lung cancer who developed Hu-associated limbic encephalitis while being treated with atezolizumab. After treatment with high-dose steroids and intravenous immunoglobulin, the neurological symptoms of the patient (including confusion, short-term memory loss, disorientation, and impaired calculation ability) remained stable for 3 months, after which the patient was lost to follow-up. ICIs may accelerate autoimmune reactions that target paraneoplastic origin autoantigens. Clinicians should be alert to the risk of ICI-induced paraneoplastic neurological syndromes in patients with tumors, such as small cell lung cancer, that are traditionally associated with paraneoplastic neurological syndromes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.